10-Q · August 19, 2026
The supplied extract covers Part II of the June 30, 2026 10-Q and does not include the financial statements, MD&A, balance sheet, cash-flow statement, or segment disclosures needed to assess revenue, margins, EPS,…
10-Q · Filed November 16, 2026 · Our reading of the company's report
The latest report
The filing excerpt provides limited operating and balance-sheet detail, but the reported Q2 2026 results were revenue of $4.334 million and diluted EPS of negative $0.046. Internal controls were deemed effective, with…
The filing excerpt provides limited operating and balance-sheet detail, but the reported Q2 2026 results were revenue of $4.334 million and diluted EPS of negative $0.046. Internal controls were deemed effective, with no material control changes reported. The most significant disclosed concern is potential shareholder dilution from the conversion of 25 preferred shares into 4,354,504 common shares, including 2,854,504 shares still issuable at September 30, 2026. No quantitative forward guidance was provided.
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Management reported that disclosure controls and procedures were effective as of September 30, 2026, based on the evaluation by the CEO and CFO.
The company stated that there were no material changes to internal control over financial reporting during the quarter ended September 30, 2026.
The company reported quarterly revenue of $4.334 million and diluted EPS of negative $0.046 for Q2 2026.
A conversion notice covering 25 shares of Series B Preferred Stock and accrued dividends resulted in an aggregate conversion into 4,354,504 common shares; 2,854,504 shares remained to be issued as of September 30, 2026, creating substantial dilution risk.
The company issued 56,818 common shares with a fair value of $6,136 as consideration for services during September 2026, indicating use of equity to settle operating obligations.
Although no material legal proceedings were pending, the company disclosed that litigation could generate defense and settlement costs and divert management resources; the filing identified 0 current material proceedings.
The provided filing text contains no quantitative revenue or EPS guidance, outlook, liquidity outlook, or capital-spending forecast.
The supplied extract covers Part II of the June 30, 2026 10-Q and does not include the financial statements, MD&A, balance sheet, cash-flow statement, or segment disclosures needed to assess revenue, margins, EPS,…
Biotricity delivered a meaningful operating inflection in FY2026: revenue rose 16.0% to $15.998 million, gross margin expanded to 81.0%, and operating income reached $1.691 million. Growth is increasingly driven by…
Biotricity reported $3.988 million of revenue and diluted EPS of $(0.042) for the reported quarter; EPS exceeded the supplied consensus estimate, but revenue was approximately 2.7% below expectations. The extracted…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.
The free pages stop at the last full session. Trader shows every trade as it prints.